Penny Stocks Of Companies Working On Long Covid
Post# of 25585
(Total Views: 217)
Posted On: 11/15/2022 4:31:57 AM
Penny Stocks Of Companies Working On Long Covid
There are a number of small companies are working on long Covid treatments.
More than four in survey of 10 people said that they knew someone with long Covid, a condition where symptoms persist for several weeks or longer. (Personally, 3 people i knew got covid in the same week out of the blue)
Long Covid is particularly complicated because there's no set list of symptoms. The Centers for Disease Control and Prevention notes a wide array of ongoing health problems (https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html) that could include fatigue, shortness of breath, neurological and digestive symptoms as well as joint or muscle pain.
But so far, large companies are shying away from treating the condition.
Instead, small companies have taken up the mantle in long Covid treatment. They include Axcella Therapeutics (AXLA), First Wave BioPharma (FWBI), Ampio Pharmaceuticals (AMPE), Regencell Bioscience (RGC), Aim ImmunoTech (AIM), Tonix Pharmaceuticals (TNXP) and privately held Humanetics.
Hong Kong-based **Regencell Bioscience** is an early clinical stage bioscience company, founded in 2014, is in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
The company’s formula aims to treat the core causes of disorders while reducing the symptoms and improving overall health of its patients at the same time. The direction of using natural ingredients (herbs) to treat elements in the body is taken as the company’s holistic approach toward the treatment process while preparing the TCM formulae for its patients.
[https://www.investors.com/news/technology/long-covid-treatments-here-are-the-penny-stocks-working-on-this-growing-problem/](https://www.investors.com/news/technology/long-covid-treatments-here-are-the-penny-stocks-working-on-this-growing-problem/)
There are a number of small companies are working on long Covid treatments.
More than four in survey of 10 people said that they knew someone with long Covid, a condition where symptoms persist for several weeks or longer. (Personally, 3 people i knew got covid in the same week out of the blue)
Long Covid is particularly complicated because there's no set list of symptoms. The Centers for Disease Control and Prevention notes a wide array of ongoing health problems (https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html) that could include fatigue, shortness of breath, neurological and digestive symptoms as well as joint or muscle pain.
But so far, large companies are shying away from treating the condition.
Instead, small companies have taken up the mantle in long Covid treatment. They include Axcella Therapeutics (AXLA), First Wave BioPharma (FWBI), Ampio Pharmaceuticals (AMPE), Regencell Bioscience (RGC), Aim ImmunoTech (AIM), Tonix Pharmaceuticals (TNXP) and privately held Humanetics.
Hong Kong-based **Regencell Bioscience** is an early clinical stage bioscience company, founded in 2014, is in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
The company’s formula aims to treat the core causes of disorders while reducing the symptoms and improving overall health of its patients at the same time. The direction of using natural ingredients (herbs) to treat elements in the body is taken as the company’s holistic approach toward the treatment process while preparing the TCM formulae for its patients.
[https://www.investors.com/news/technology/long-covid-treatments-here-are-the-penny-stocks-working-on-this-growing-problem/](https://www.investors.com/news/technology/long-covid-treatments-here-are-the-penny-stocks-working-on-this-growing-problem/)
(0)
(0)